Cialis 20 mg

Tadalafil

Erectile dysfunction (ED).

Adult Recommended starting dose: 10 mg prior to anticipated sexual activity. May be increased to 20 mg or decreased to 5 mg, based on individual efficacy & tolerability. Max recommended dosing frequency: Once daily. Renal impairment CrCl 30-50 mL min Initially 5 mg once daily. Max: 10 mg not more than once in every 48 hr, CrCl <30 mL/min or on hemodialysis Max: 5 mg not more than once in every 72 hr. Mild or moderate hepatic impairment (Child-Pugh class A or B) Not to exceed 10 mg once daily.

May be taken with or without food: Do not split.

Hypersensitivity. Concomitant use w/ any form of organic nitrate & guanylate cyclase (GC) stimulators.

Not indicated for use in women. Not to be used in men w/ cardiac disease for whom sexual activity is inadvisable. At least 48 hr should have elapsed after the last dose before considering nitrate administration. Patients w/ left ventricular outflow obstruction (eg, aortic stenosis & idiopathic hypertrophic subaortic stenosis); severely impaired autonomic BP control. Not recommended in patients w/ MI w/in the last 90 days; unstable angina or angina occurring during sexual intercourse; NYHA class ≥2 heart failure in the last 6 mth; uncontrolled arrhythmias, hypotension (<90/50 mmHg), or uncontrolled HTN stroke w/in the last 6 mth. Priapism-predisposing conditions (eg, sickle cell anemia, multiple myeloma or leukemia) or w/ anatomical deformation of the penis (eg, angulation, cavernosal fibrosis or Peyronie's disease). Not recommended in combinations w/ other treatments for erectile dysfunction or other PDE5 inhibitors. Symptomatic hypotension in patients taking α₁-blockers (eg, doxazosin). Nonarteritic anterior ischemic optic neuropathy (NAION). Discontinue in the event of a sudden loss of vision. Not recommended for patients w/ known hereditary degenerative retinal disorders including retinitis pigmentosa. Discontinue in the event of sudden decrease or loss of hearing. Patients w/ bleeding disorders or significant active peptic ulceration. May affect ability to drive or operate machinery. Renal impairment. Not recommended in patients w/ severe hepatic impairment (Child-Pugh class C). Pregnancy. Not to be used in childn <18 yr.

Headache, dyspepsia, back pain, myalgia, nasal congestion, flushing, pain in limb.

Increased exposure (AUC) & C_max w/ selective CYP3A4 inhibitor eg, ketoconazole. Increased exposure (AUC) w/ ritonavir, other HIV PIs (eg, saquinavir) & other CYP3A4 inhibitors (eg, erythromycin & itraconazole). Reduced exposure (AUC) & C_max w/ selective CYP3A4 inducers eg, rifampicin. Reduced apparent rate of absorption w/o altering exposure (AUC) w/ antacid (Mg hydroxide/Al hydroxide). Potentiated hypotensive effects of nitrates & BP-lowering effects of antihypertensives & doxazosin. Additive effect on BP w/ α-blockers. Increase potential for orthostatic signs & symptoms w/ substantial consumption of alcohol.

Drugs for Erectile Dysfunction & Ejaculatory Disorders

G04BE08 - tadalafil ; Belongs to the class of drugs used in erectile dysfunction.

Rx